Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant

Kei Miyakawa, Sundararaj Stanleyraj Jeremiah, Hideaki Kato, Akihide Ryo
doi: https://doi.org/10.1101/2021.09.23.21264014

Article Information

doi 
https://doi.org/10.1101/2021.09.23.21264014
History 
  • September 26, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Kei Miyakawa1,*,
  2. Sundararaj Stanleyraj Jeremiah1,
  3. Hideaki Kato2 and
  4. Akihide Ryo1,*
  1. 1Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
  2. 2Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan
  1. ↵*Corresponding authors Kei Miyakawa (keim{at}yokohama-cu.ac.jp), Akihide Ryo (aryo{at}yokohama-cu.ac.jp), Department of Microbiology, Yokohama City University School of Medicine, 3-9 Fuku-ura, Kanazawa, Yokohama 236-0004, Japan
Back to top
Posted September 26, 2021.
Download PDF
Data/Code
Email
Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant
Kei Miyakawa, Sundararaj Stanleyraj Jeremiah, Hideaki Kato, Akihide Ryo
medRxiv 2021.09.23.21264014; doi: https://doi.org/10.1101/2021.09.23.21264014
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area